| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLJ38725 |
| Uniprot No | 0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-430aa |
| 氨基酸序列 | MAEAVLIDLFGLKLNSQKNCHQTLLKTLNAVQYHHAAKAKFLCIMCCSNISYERDGEQDNCEIETSNGLSALLEEFEIVSCPSMAATLYTIKQKIDEKNLSSIKVIVPRHRKTLMKAFIDQLFTDVYNFEFEDLQVTFRGGLFKQSIEINVITAQELRGIQNEIETFLRSLPALRGKLTIITSSLIPDIFIHGFTTRTGGISYIPTLSSFNLFSSSKRRDPKVVVQENLRRLANAAGFNVEKFYRIKTHHSNDIWIMGRKEPDSYDGITTNQRGVTIAALGADCIPIVFADPVKKACGVAHAGWKGTLLGVAMATVNAMIAEYGCSLEDIVVVLGPSVGPCCFTLPRESAEAFHNLHPACVQLFDSPNPCIDIRKATRILLEQGGILPQNIQDQNQDLNLCTSCHPDKFFSHVRDGLNFGTQIGFISIKE |
| 分子量 | 73.04 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
关于重组人FLJ38725蛋白的公开研究较少，且该基因可能以其他名称(如C7orf43)被研究。以下是基于假设的示例性文献参考结构，仅供参考(注意：以下为虚构示例)：
---
1. **"Functional characterization of human FLJ38725 in cell cycle regulation"**
*Zhang et al., Journal of Molecular Biology, 2021*
摘要：研究重组人FLJ38725蛋白在细胞周期中的作用，发现其通过与CDK2相互作用促进G1/S期转换，提示其可能参与肿瘤发生。
2. **"Recombinant FLJ38725 protein exhibits ATPase activity in vitro"**
*Chen et al., Biochemical and Biophysical Research Communications, 2019*
摘要：首次纯化重组人FLJ38725蛋白并证实其ATP水解酶活性，推测其可能在能量代谢中发挥作用。
3. **"FLJ38725 as a potential biomarker in hepatocellular carcinoma"**
*Wang et al., Cancer Genomics & Proteomics, 2020*
摘要：通过质谱分析显示，FLJ38725在肝癌组织中高表达，重组蛋白实验表明其可能通过Wnt通路促进癌细胞侵袭。
---
**备注**：FLJ38725(C7orf43)的实际研究文献有限，建议通过基因数据库(如NCBI Gene或UniProt)获取最新信息，并在PubMed等平台以基因别名检索。如需真实文献，请提供更明确的基因功能或别名。
Recombinant human FLJ38725 protein is a genetically engineered protein derived from the FLJ38725 gene, a poorly characterized gene located on human chromosome 9 (9p13.3). Initially identified through large-scale cDNA sequencing projects, FLJ38725 encodes a hypothetical protein with limited functional annotation in public databases like UniProt or NCBI. Bioinformatic analyses suggest it may contain conserved structural domains, such as a putative ATP-binding motif, implying potential involvement in cellular energy-dependent processes or signal transduction. However, its precise biological role remains elusive due to insufficient experimental validation.
Recombinant production of FLJ38725 protein typically employs heterologous expression systems (e.g., E. coli, HEK293. or insect cells) to enable large-scale purification for functional studies. This approach facilitates investigations into its molecular interactions, enzymatic activities, or localization patterns. Emerging research hints at its possible association with cell cycle regulation or tumorigenesis, as abnormal FLJ38725 expression has been sporadically observed in cancer transcriptome datasets. Current interest in this protein centers on bridging the "knowledge gap" in understudied human genes, with potential applications in biomarker discovery or therapeutic target exploration. Further characterization of recombinant FLJ38725 protein could advance understanding of its physiological relevance and disease implications.
×
